Working… Menu

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02531516
Recruitment Status : Active, not recruiting
First Posted : August 24, 2015
Last Update Posted : September 20, 2019
Information provided by (Responsible Party):
Aragon Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Drug: Apalutamide Drug: Bicalutamide Drug: Bicalutamide Placebo Drug: Apalutamide Placebo Drug: GnRH (agonist) Radiation: 74-80 Grays (units of radiation) Phase 3

Detailed Description:
This is a randomized, double-blind, placebo-controlled, multicenter study of apalutamide plus GnRH agonist compared with GnRH agonist among participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT). The study will include a Screening Phase, Treatment Phase, a Posttreatment Phase, and a Long-term Follow-up Phase. Participants will either receive either apalutamide (experimental) or bicalutamide 50 milligram (mg) capsule plus placebo as control group. Safety will be monitored throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1503 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
Actual Study Start Date : November 19, 2015
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : October 6, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Apalutamide

Arm Intervention/treatment
Experimental: Apalutamide
Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
Drug: Apalutamide
Drug: Bicalutamide Placebo
Drug: GnRH (agonist)
Radiation: 74-80 Grays (units of radiation)
Active Comparator: Control group
Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
Drug: Bicalutamide
Drug: Apalutamide Placebo
Drug: GnRH (agonist)
Radiation: 74-80 Grays (units of radiation)

Primary Outcome Measures :
  1. Metastasis-free survival [ Time Frame: 84 Months ]

Secondary Outcome Measures :
  1. Time to Local-regional Recurrence [ Time Frame: 84 Months ]
  2. Time to Castration-resistant Prostate Cancer (CRPC) [ Time Frame: 84 Months ]
  3. Time to Distant Metastasis [ Time Frame: 84 Months ]
  4. Overall Survival (OS) [ Time Frame: 84 Months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >= 18 years
  • Indicated and planned to receive primary radiation therapy for prostate cancer
  • Histologically confirmed adenocarcinoma of an intact prostate, and 1 of the following at diagnosis: 1) Gleason score >=8 and >=cT2c, 2) Gleason score >=7, PSA >=20 nanogram per milliliters (ng/mL), and >=cT2c
  • Charlson index (CCI) <=3
  • An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) grade of 0 or 1
  • Adequate organ function: (1) aspartate aminotransferase (AST), alanine aminotransferase (ALT), within normal limits (WNL), (2) serum creatinine less than (<) 1.5 milligram/deciliter (mg/dL) (<133 micromoles/Liter [mcmol/L]), (3) platelets greater than or equal to (>=)140,000/microLiter (mcL), independent of transfusion and/or growth factors within 3 months prior to randomization, (4) Hemoglobin >= 12.0 gram/deciliter (g/dL) (7.4 millimloes [mmol], independent of transfusion and/or growth factors within 3 months prior to randomization
  • Participants who are sexually active (even men with vasectomies) and willing to use a condom and agree not to donate sperm during the trial
  • Signed, written, informed consent
  • Be able to swallow whole study drug tablets

Exclusion Criteria: -

  • Presence of distant metastasis, (clinical stage M1). Isolated pelvic nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage; N1 versus N0) will be assessed by central radiological review. Patients are considered eligible only if the central radiological review confirms clinical stage M0.
  • Prior treatment with gonadotropin releasing hormone (GnRH) analogue or anti-androgen or both for >3 months prior to randomization
  • Bilateral orchiectomy
  • History of pelvic radiation
  • Prior systemic (example [e.g.], chemotherapy) or local (e.g. radical prostatectomy, cryotherapy) treatment for prostate cancer
  • History of seizure or any condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness <= 1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
  • Prior treatment with enzalutamide, abiraterone acetate, orteronel, galeterone, ketoconazole, aminoglutethimide, estrogens, megestrol acetate, and progestational agents (including cyproterone acetate) for prostate cancer
  • Prior treatment with radiopharmaceutical agents (e.g., strontium-89) or immunotherapy (e.g., sipuleucel-T) for prostate cancer
  • Prior treatment with systemic glucocorticoids ≤4 weeks prior to randomization or is expected to require long-term use of corticosteroids during the study
  • Use of 5-alpha reductase inhibitors (e.g., dutasteride, finasteride) <=4 weeks prior to randomization
  • Use of any investigational agent <=4 weeks prior to randomization
  • Current chronic use of opioid analgesics for >=3 weeks for oral or >7 days for non-oral formulations
  • Major surgery <=4 weeks prior to randomization
  • Current or prior treatment with anti-epileptic medications for the treatment of seizures
  • Gastrointestinal conditions affecting absorption
  • Known or suspected contraindications or hypersensitivity to apalutamide, bicalutamide or GnRH agonists or any of the components of the formulations
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02531516

  Hide Study Locations
Layout table for location information
United States, Alabama
Homewood, Alabama, United States
United States, Arizona
Chandler, Arizona, United States
Scottsdale, Arizona, United States
Tucson, Arizona, United States
United States, California
Bakersfield, California, United States
Los Angeles, California, United States
Orange, California, United States
San Bernardino, California, United States
San Diego, California, United States
San Francisco, California, United States
United States, Colorado
Aurora, Colorado, United States
Denver, Colorado, United States
United States, Connecticut
Middlebury, Connecticut, United States
United States, Florida
Bradenton, Florida, United States
Daytona Beach, Florida, United States
Fort Myers, Florida, United States
Hialeah, Florida, United States
Lakewood Ranch, Florida, United States
Naples, Florida, United States
Plantation, Florida, United States
United States, Idaho
Meridian, Idaho, United States
United States, Illinois
Evergreen Park, Illinois, United States
Harvey, Illinois, United States
United States, Indiana
Jeffersonville, Indiana, United States
United States, Kansas
Wichita, Kansas, United States
United States, Kentucky
Ashland, Kentucky, United States
United States, Louisiana
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
United States, Maine
Scarborough, Maine, United States
United States, Maryland
Baltimore, Maryland, United States
Owings Mills, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Missouri
Saint Louis, Missouri, United States
United States, New Jersey
Morristown, New Jersey, United States
United States, New York
Albany, New York, United States
Bronx, New York, United States
Brooklyn, New York, United States
New York, New York, United States
Poughkeepsie, New York, United States
Rochester, New York, United States
Syracuse, New York, United States
United States, North Carolina
Cary, North Carolina, United States
Raleigh, North Carolina, United States
United States, Oregon
Portland, Oregon, United States
Springfield, Oregon, United States
United States, Pennsylvania
Bala-Cynwyd, Pennsylvania, United States
Bryn Mawr, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, Rhode Island
Warwick, Rhode Island, United States
United States, South Carolina
Charleston, South Carolina, United States
Myrtle Beach, South Carolina, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
United States, Virginia
Fairfax, Virginia, United States
Virginia Beach, Virginia, United States
United States, Washington
Burien, Washington, United States
Spokane, Washington, United States
United States, West Virginia
Morgantown, West Virginia, United States
C.a.b.a., Argentina
Caba, Argentina
Capital Federal, Argentina
Ciudad Autonoma de Buenos Aires, Argentina
Pergamino, Argentina
Rosario, Argentina
San Salvador de Jujuy, Argentina
Aalst, Belgium
Bonheiden, Belgium
Brussel, Belgium
Haine-St-Paul, Belgium
Leuven, Belgium
Liège, Belgium
Namur, Belgium
Roeselare, Belgium
Sint-Niklaas, Belgium
Turnhout, Belgium
Wilrijk, Belgium
Barretos, Brazil
Belo Horizonte, Brazil
Campinas, Brazil
Curitiba, Brazil
Florianópolis, Brazil
Goiânia, Brazil
Ijui, Brazil
Natal, Brazil
Porto Alegre, Brazil
Ribeirao Preto, Brazil
Rio de Janeiro, Brazil
Salvador, Brazil
Santo André, Brazil
Sao Jose do Rio Preto, Brazil
Sao Paulo, Brazil
Sorocaba, Brazil
São Paulo, Brazil
Canada, Alberta
Calgary, Alberta, Canada
Canada, British Columbia
Surrey, British Columbia, Canada
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
Canada, Ontario
London, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Gatineau, Quebec, Canada
Laval, Quebec, Canada
Montreal, Quebec, Canada
Montréal, Quebec, Canada
Sherbrooke, Quebec, Canada
Quebec, Canada
Beijing, China
ChengDu, China
ChongQing, China
GuangZhou, China
Hangzhou, China
Nanchang, China
NanJing, China
Ningbo, China
ShangHai, China
Wuhan, China
Xi'An, China
Hradec Králove, Czechia
Liberec, Czechia
Nový Jicin, Czechia
Olomouc, Czechia
Opava, Czechia
Pardubice, Czechia
Praha 10, Czechia
Praha 2, Czechia
Praha 4, Czechia
Praha 5, Czechia
Praha 8, Czechia
Zlin, Czechia
Amiens, France
Angers Cedex 02, France
Avignon Cedex 9, France
Bayonne, France
Besancon, France
Bordeaux, France
Brest, France
Dijon, France
Hyères, France
La Tronche, France
Le Mans, France
Lille, France
Marseille cedex 05, France
Marseilli, France
Montpellier, France
Neuilly-sur-Seine, France
Paris, France
Ris Orangis, France
Saint Herblain, France
Saint-Brieuc, France
Saint-Mandé, France
Saint-Priest-en-Jarez, France
Strasbourg, France
Toulouse, France
Tours, France
Vandoeuvre-les-Nancy, France
Villejuif Cedex, France
Braunschweig, Germany
Chemnitz, Germany
Dessau, Germany
Frankfurt, Germany
Gronau, Germany
Jena, Germany
Münster, Germany
Nürtingen, Germany
Ulm, Germany
Weiden, Germany
Beer Yaakov, Israel
Beer-Sheva, Israel
Haifa, Israel
Jerusalem, Israel
Kfar Saba, Israel
Petach-Tikva, Israel
Ramat-Gan, Israel
Tel-Aviv, Israel
Korea, Republic of
Daegu, Korea, Republic of
Hwasun-gun, Korea, Republic of
Seongnam-si, Gyeonggi-do, Korea, Republic of
Seoul, Korea, Republic of
Suwon-si, Korea, Republic of
Georgetown, Malaysia
Kuala Lumpur, Malaysia
Kuching, Malaysia
Putrajaya, Malaysia
Culiacan, Mexico
Guadalajara, Mexico
Leon, Mexico
Mexico, Mexico
Morelia, Mexico
Zapopan, Mexico
Alkmaar, Netherlands
Amsterdam, Netherlands
Den Haag, Netherlands
Nijmegen, Netherlands
Rotterdam, Netherlands
Bialystok, Poland
Bydgoszcz, Poland
Gdynia, Poland
Gliwice, Poland
Kielce, Poland
Lodz, Poland
Olsztyn, Poland
Poznan, Poland
Walbrzych, Poland
Bucuresti, Romania
Cluj-Napoca, Romania
Floresti, Romania
Iasi, Romania
Otopeni, Romania
Ploiesti, Romania
Sibiu, Romania
Targu Mures, Romania
Timisoara, Romania
Russian Federation
Barnaul, Russian Federation
Ivanovo, Russian Federation
Moscow, Russian Federation
Nizhny Novgorod, Russian Federation
Obninsk, Russian Federation
Omsk, Russian Federation
Pyatigorsk, Russian Federation
Rostov-on-Don, Russian Federation
Ryazan, Russian Federation
Saint-Petersburg, Russian Federation
Saransk, Russian Federation
St Petersburg, Russian Federation
Tambov, Russian Federation
Tyumen, Russian Federation
Ufa, Russian Federation
Vologda, Russian Federation
Barakaldo, Spain
Barcelona, Spain
Castellon, Spain
Hospitalet de Llobregat, Spain
Las Palmas de Gran Canaria, Spain
Madrid, Spain
Málaga, Spain
Reus, Spain
Santiago de Compostela, Spain
Sevilla, Spain
Stockholm, Sweden
Umeå, Sweden
Örebro, Sweden
Kaohsiung, Taiwan
Taichung, Taiwan
Tainan, Taiwan
Taipei City, Taiwan
Taipei, Taiwan
Taoyuan, Taiwan
Adana, Turkey
Ankara, Turkey
Edirne, Turkey
Istanbul, Turkey
İzmir, Turkey
Kayseri, Turkey
Kocaeli, Turkey
Dnipro, Ukraine
Khakhiv, Ukraine
Kyiv, Ukraine
Lviv, Ukraine
United Kingdom
Aberdeen, United Kingdom
Birmingham, United Kingdom
Bristol, United Kingdom
Derby, United Kingdom
Glasgow, United Kingdom
Oxford, United Kingdom
Plymouth, United Kingdom
Preston, United Kingdom
Sheffield, United Kingdom
Sutton, United Kingdom
Wolverhampton, United Kingdom
Sponsors and Collaborators
Aragon Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: Aragon Pharmaceuticals, Inc. Clinical Trial Aragon Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Aragon Pharmaceuticals, Inc. Identifier: NCT02531516     History of Changes
Other Study ID Numbers: CR106935
56021927PCR3003 ( Other Identifier: Aragon Pharmaceuticals, Inc. )
2015-003007-38 ( EudraCT Number )
First Posted: August 24, 2015    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aragon Pharmaceuticals, Inc.:
Prostatic neoplasms
Prostate Cancer
High-Risk prostate cancer
Long-term hormone therapy
Localized or locally advanced prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Androgen Antagonists
Hormone Antagonists
Antineoplastic Agents